Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a report published on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $21.00 price target on the stock.

Other equities analysts have also issued research reports about the stock. Bank of America boosted their target price on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX opened at $14.11 on Tuesday. The stock has a 50-day simple moving average of $13.82 and a 200 day simple moving average of $13.15. Amylyx Pharmaceuticals has a twelve month low of $2.60 and a twelve month high of $17.49. The stock has a market capitalization of $1.55 billion, a PE ratio of -7.84 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30). As a group, equities research analysts forecast that Amylyx Pharmaceuticals will post -2.2 EPS for the current fiscal year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, CFO James M. Frates sold 3,326 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $11.11, for a total transaction of $36,951.86. Following the completion of the transaction, the chief financial officer directly owned 177,104 shares of the company’s stock, valued at approximately $1,967,625.44. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joshua B. Cohen sold 136,193 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $13.59, for a total transaction of $1,850,862.87. Following the completion of the transaction, the chief executive officer directly owned 3,378,621 shares of the company’s stock, valued at $45,915,459.39. This trade represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 151,203 shares of company stock valued at $2,028,385 over the last quarter. 12.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AMLX. Landscape Capital Management L.L.C. grew its position in Amylyx Pharmaceuticals by 17.5% in the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after acquiring an additional 1,825 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Amylyx Pharmaceuticals by 54.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after acquiring an additional 1,890 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $25,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Amylyx Pharmaceuticals by 14.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock worth $216,000 after purchasing an additional 2,265 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Amylyx Pharmaceuticals by 13.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company’s stock worth $326,000 after purchasing an additional 3,198 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Stifel Nicolaus initiated coverage with a “buy” rating and a $21.00 price target (~48.8% above the current price). Analyst initiation and a sizable target can attract buyers and provide a near-term positive catalyst. Benzinga Article
• Neutral Sentiment: Company reported Q4 and full-year 2025 results and posted EPS of ($0.30), which matched consensus — no earnings surprise. Investors often trade on beats/misses; meeting estimates is neutral but can disappoint if expectations were higher. Amylyx Reports Q4/2025 Results (Yahoo)
• Neutral Sentiment: Earnings call transcript is available for investors who want management commentary on revenue trends, commercial uptake, cash runway, and 2026 outlook — details in the call may influence sentiment once parsed. Earnings Call Transcript
• Neutral Sentiment: MarketBeat/press release links and a pre-release projection article were posted around the results — useful for investors wanting official figures and conference call audio. Press Release (MarketBeat/Quartr) and Projected Earnings (AmericanBankingNews)
• Neutral Sentiment: Short-interest data published overnight shows anomalous values (0 shares/NaN changes and 0.0 days-to-cover). The figures appear to be data errors rather than a true indicator of rising short pressure; investors should treat these reports with caution until corrected. (No external link provided.)

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.